Journal: iScience

Article Title: MFAP5 + synovial fibroblasts drive LOX upregulation to promote osteoarthritis progression

doi: 10.1016/j.isci.2026.116286

Figure Lengend Snippet: MFAP5 + SFs promoted collagen deposition in synovium (A) Dendrogram showing the hierarchy organization of MEGENA network modules in GSE176308 . The top layer represented the root and largest parent modules, which branched hierarchically into smaller child modules. (B) Density plots displaying c1_9 module scores across SF clusters, with color-coded density values; red indicated higher density, and blue indicated lower density. (C) Network of pathways and genes involved in the c1_9 module, where a two-point line indicated that a gene was part of a specific pathway. (D) Raincloud plot showing c1_9 score in GSE152805 . (E and F) Gene set enrichment analysis showed collagen pathways were upregulated in MFAP5 + SFs in both GSE176308 (E) and GSE152805 (F). (G) Correlation coefficients between the expression of MFAP5 and one ECM pathway score across three datasets. (H) Violin plots of ECM binding (left) and ECM organization (right) scores across SF clusters in GSE176308 . Color-coded by SF clusters. (I) Density plots of ECM binding and ECM organization scores across SF clusters in SCP469 and GSE152805 . (J) Comparison of significant ligand-receptor pairs from SF clusters to T cells in GSE152805 . (K) Immunofluorescence images of MFAP5, CD4, and vimentin colocalization in synovial tissues. Scale bars, 200 or 20 μm. Statistical significance was calculated using two-tailed Wilcoxon rank-sum test (D and H) and Spearman's rank correlation analysis (G). ∗∗∗ p < 0.001.

Article Snippet: Sections were then incubated overnight at 4 °C with primary antibodies, including vimentin (GB11192, Servicebio, China), FBN1 (860327, Zenbio, China), MFAP5 (15727-1-AP, Proteintech, China), and CD4 (GB150062-50, Servicebio, China).

Techniques: Expressing, Binding Assay, Comparison, Immunofluorescence, Two Tailed Test

Journal: Nature Medicine

Article Title: Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial

doi: 10.1038/s41591-026-04449-9

Figure Lengend Snippet: Flow immunophenotyping release testing data are presented in A-G and IFNγ ELISpot data presented in H-K (Arm A: n = 12; Arms B/C: n = 27). Each data point represents a separate TAA-T cell product infused into patients (biological replicates). Lower whisker is defined as the minima, upper whisker is defined as the maxima, center is defined as median, lower bound of box is defined as Q1 (25th percentile), and upper bound of box is defined as Q3 (75th percentile). a ) % Total T cells (CD3 + ). Arm A: Minima=51, Maxima=99, Median=97, 25th Percentile=95, 75th Percentile=99; Arms B/C: Minima=31, Maxima=100, Median=97, 25th Percentile=94, 75th Percentile=98. b ) % CD4 + T cells (CD3 + CD4+ of CD45 + ). Arm A: Minima=0.50, Maxima=88, Median=16, 25th Percentile=2.6, 75th Percentile=38; Arms B/C: Minima=0.40, Maxima=55, Median=9.9, 25th Percentile=6.1, 75th Percentile=17. c ) %CD8 + T cells (% CD3 + CD8+ of CD45 + ). Arm A: Minima=4.3, Maxima=88, Median=37, 25th Percentile=22, 75th Percentile=47; Arms B/C: Minima=19, Maxima=91, Median=51, 25th Percentile=36, 75th Percentile=71. d ) % αβ T cells (% TCRαβ+ of CD3 + ). Arm A: Minima=8.2, Maxima=94, Median=69, 25th Percentile=28, 75th Percentile=86; Arms B/C: Minima=32, Maxima=98, Median=71, 25th Percentile=48, 75th Percentile=84. e ) % γδ T cells (% TCRγδ+ of CD3 + ). Arm A: Minima=5.1, Maxima=79, Median=28, 25th Percentile=8.4, 75th Percentile=67; Arms B/C: Minima=1.1, Maxima=83, Median=25, 25th Percentile=10, 75th Percentile=53. f ) % CD3 + CD16 + CD56+ of CD45 + . Arm A: Minima=2.8, Maxima=25, Median=11, 25th Percentile=7.2, 75th Percentile=17; Arms B/C: Minima=3.4, Maxima=64, Median=16, 25th Percentile=8.1, 75th Percentile=28. g ) % NK cells (CD16/CD56 + CD3- of CD45 + ). Arm A: Minima=0.40, Maxima=48, Median=1.0, 25th Percentile=0.48, 75th Percentile=4.6; Arms B/C: Minima=0.10, Maxima=62, Median=1.6, 25th Percentile=0.60, 75th Percentile=6.1. h - i ) IFNγ ELISpot with background correction for Arm A ( h ) and Arms B/C ( i ). Negative values after background normalization have been normalized to zero for visual representation.

Article Snippet: An FcR blocking agent (Miltenyi Biotec, cat. no. 130-059-901) was added to the tubes for 5 min to prevent any nonspecific binding, followed by an appropriate antibody mix (shown in tables below), which was incubated in the dark for 15 min. Antibodies for the pan leukocyte panel included CD14 Vio Blue (Miltenyi Biotec, cat. no. 130-110-524), CD19 FITC (Miltenyi Biotec, cat. no. 130-113-646), CD16 PE (Miltenyi Biotec, cat. no. 130-113-393), CD56 PE (Miltenyi Biotec, cat. no. 130-113-312), CD3 Per CP Vio-770 (Miltenyi Biotec, cat. no. 130-113-141), CD4 PE-Vio-770 (Miltenyi Biotec, cat. no. 130-113-227), CD45 APC (Miltenyi Biotec, cat. no. 130-110-633) and CD8 APC Vio-770 (Miltenyi Biotec, cat. no. 130-110-681).

Techniques: Enzyme-linked Immunospot, Whisker Assay